NHS Framework for the North of England, Branded Medicine

Tender description

HS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®) Lot 1: CM/PHR/20/5600/01 - NHS Framework for the NOFE, Branded Medicines - Tranche B CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months Lot 2: CM/PHR/20/5600/02 - NHS Framework for the NOFE, Branded Medicines-Annual Tranche CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Lot 3: CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months. Lot 4: CM/PHR/20/5600/04-NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 18 months. Lot 5: CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.